hairy cell leukemia variant
hairy cell leukemia variant
Explore linked clinical trials. Standard reference: MONDO:00176003 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hairy cell leukemia variant, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-09-16 | NCT04815356 | |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hairy cell leukemia variant, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT01841723 | |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hairy cell leukemia variant, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Enrolling by invitation | Phase 2 | 2026-07-08 | NCT07690761 |